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Abstract
Background: Baló’s concentric sclerosis (BCS) is a rare inflammatory demyelinating disorder of the central nervous
system characterised by concentric layers of demyelination. It is unclear whether BCS is a variant of multiple
sclerosis (MS) or a disease entity in its own right.
Objective: To compare the cerebrospinal fluid (CSF) features of BCS to those of MS.
Methods: Retrospective analysis of the CSF profile of all patients with BCS reported in the medical literature
between 1980 and 2017.
Results: In total, the results of 146 lumbar punctures (LP) in 132 patients were analysed. The most striking
finding was a lack of CSF-restricted oligoclonal bands (OCB) in 66% (56/85) of all LP in the total BCS group,
in 74% (14/19) in the subgroup of patients with both MRI and histological evidence for BCS, and in 82% (18/
22) in the subgroup of patients with highest radiological confidence (high MRI quality, ≥ 3 layers of
demyelination). OCB disappeared in 1/2 initially OCB-positive patients. These findings are in stark contrast to
MS, in which OCB are present in ≥ 95% of patients and are thought to remain stably detectable over the
entire course of disease (p < 0.000001). OCB frequency was low both in ‘historic’ patients (1980–2009; 37%)
and in more recent patients (2010–2017; 31%). OCB-positive and OCB-negative patients did not differ significantly
with regard to age, sex, disease duration, number of Baló-like lesions on MRI, number of relapses, treatment or final
outcome. In accordance with the high rate of OCB negativity, Link’s IgG index was negative in 63% of all tested samples
(p < 0.000001 vs. MS). CSF pleocytosis was present in 28% (27/96; p < 0.000001 vs. MS) and elevated CSF total protein
levels in 41% (31/76) of samples.
Conclusion: OCB and IgG index frequencies in BCS are much more similar to those reported in neuromyelitis optica or
myelin oligodendrocyte glycoprotein antibody-associated encephalomyelitis than to those in MS. Our findings suggest
that in most cases BCS-like lesions denote the presence of a disease entity immunologically distinct from MS. In addition,
we provide data on the demographics, clinical course and radiological features of BCS based on the largest cohort
analysed to date.
Keywords: Baló’s concentric sclerosis (BCS), Baló, Multiple sclerosis (MS), Cerebrospinal fluid (CSF), Lumbar
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Background
Baló’s concentric sclerosis (BCS) is a rare demyelinating
disorder of the central nervous system (CNS) charac-
terised by concentric layers of demyelination as detected
by MRI or histopathology, and named after the Hungarian
pathologist József Baló (1895-1979) [1, 2]. BCS is often
regarded as a rare variant of multiple sclerosis (MS).
While there are indeed similarities in terms of clinical
presentation, BCS differs in several aspects from typical
MS: lesion morphology (onion-like configuration charac-
terised by concentric, alternating layers of demyelinated
and myelinated tissue), lesion size (high frequency of large
or ‘tumefactive’ lesions), disease course (often monophasic
and self-limiting rather than relapsing-remitting) and dis-
ease severity (not uncommonly fatal at first occurrence).
This suggests that BCS and MS may be distinct disorders.
In a number of studies, we have demonstrated highly
significant differences in cerebrospinal fluid (CSF) features
between patients with MS and patients with other auto-
immune disorders of the CNS. In particular, we have
found significantly lower frequencies of CSF-restricted
oligoclonal bands (OCB) and other markers of intrathecal
IgG synthesis in patients with AQP4-IgG-positive neuro-
myelitis optica (NMO) spectrum disorders (NMOSD),
myelin oligodendrocyte glycoprotein antibody-associated
encephalomyelitis (MOG-EM), acute demyelinating
encephalomyelitis (ADEM) and paraneoplastic neuro-
logical disorders (PND) than in MS, as well as significant
differences in intrathecal IgG composition and dynamics
and in blood–CSF barrier function [3–14]. This indicates
that studying CSF profiles may be helpful in distinguishing
clinically related but immunopathogenetically distinct
diseases.
To address the question of whether BCS is a variant of
multiple sclerosis (MS) or an immunologically distinct
disease entity in its own right, we therefore set out to
systematically compare the CSF features of BCS with
those in MS.
Methods
We performed a systematic review of all BCS cases pub-
lished in English, German, French, Spanish, Japanese,
Chinese, Russian or Italian in journals indexed in the
PubMed database of the US Library of Science at the US
National Institutes of Health between 1980 and 2017.
Relevant publications were identified using the following
search expression: Balo[title/abstract] OR Balo’s[title/
abstract] OR Balos[title/abstract] OR ‘concentric sclerosis’
[title/abstract]. Further publications/cases were identified
by screening the reference lists of all PubMed-retrieved
publications and from the authors’ own files. Overall, 215
publications that made mention of Baló’s concentric scler-
osis in the abstract and/or title were identified and infor-
mation on the CSF findings of 132 patients with BCS was
collected. Results from follow-up lumbar punctures
(LP) were available from 12/132 (9%) patients (10 × 2
LP, 2 × 3 LP). In total, results from 146 LP in 132
patients diagnosed with BCS were available for retro-
spective analysis.
The following CSF parameters were assessed: CSF-
restricted oligoclonal IgG bands (OCB); Link’s IgG index
([IgG CSF/IgG serum]/[albumin CSF/albumin serum]);
immunoglobulin G/A/M (IgG/A/M) CSF levels and
IgG/A/M CSF/serum ratios (QIgG/A/M); measles/ru-
bella/zoster reaction (MRZR) as defined by a positive
reaction to at least two of the three viral agents; CSF al-
bumin concentration and albumin CSF/serum ratio
(QAlb); CSF white cell count (WCC); CSF cytology; CSF
total protein concentration (TP); frequency of an albu-
minocytologic dissociation (ACD), i.e. CSF TP elevation
in the absence of CSF pleocytosis; CSF myelin basic pro-
tein concentration (MBP); and CSF lactate concentra-
tion. A CSF white cell count ≥ 5/μl was classified as
increased. An age-dependent upper reference range for
CSF L-lactate was applied (0–15 years of age, 1.8 mmol/
l; 16–50, 2.1 mmol/l; > 50, 2.6 mmol/l). The upper refer-
ence limit for total CSF protein was set at 50 mg/dl [15].
In addition, the following demographic, clinical and
paraclinical parameters were assessed: sex, ethnic origin,
age at onset, age at LP, time between last attack and LP,
attack and long-term outcome, treatment status at the
time of LP, number and location of Baló-like lesions, fre-
quency and number of coexisting non-Baló-like lesions,
initially suspected diagnosis, level of diagnostic certainty
(radiological vs. radiological plus histological evidence),
and outcome at last follow-up (fatal, no recovery, almost
no recovery, partial recovery, almost full recovery, full
recovery).
The Mann–Whitney U test and Fisher’s exact test
(two-tailed) were used to compare groups. Spearman’s r
was used to test for correlations between groups. Due to
the exploratory nature of this study, no correction for
multiple testing was performed. All analyses were per-
formed retrospectively; accordingly, no CSF or serum
samples were obtained for this study.
Results
Patient characteristics
The sex ratio (male to female) was 1:1.54. The median
age of disease onset was 32 years (range 4–57). In 68 pa-
tients, the diagnosis of BCS was based upon typical
radiological features; in 35, on typical histopathological
features; and in 25, on both typical radiological and typ-
ical histopathological features. Histopathological evi-
dence was obtained from biopsy samples in 15, from
autopsy samples in 42 and from both biopsy and autopsy
samples in 3 patients. In 43 cases, a single Baló-like le-
sion was present at the time of LP as detected by MRI
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or, if MRI was not available, histology, and multiple (me-
dian 2; range 2–9) Baló-like lesions were noted in 53
cases. Baló-like lesions were located in the supratentorial
brain at the time of LP in 93 cases, in the infratentorial
brain in 3, in both the supra- and infratentorial brain in
5 and in the supra- and/or infratentorial brain and the
spinal cord in 4. Additional non-Baló-like CNS lesions
were present in 58/94 (61.7%) patients at the time of LP.
Before the diagnosis of BCS was made, MS was initially
suspected in at least 8 patients, stroke in 5 and other
diagnoses such as ‘tumefactive demyelinating disease’,
‘brain tumour’ or ‘brain abscess’ in 8 (no data in the re-
mainder). Antibodies to aquaporin-4 (AQP4-IgG) or
myelin oligodendrocyte glycoprotein (MOG-IgG) had
been tested in 20 and 3 patients, respectively, and were
negative in all. The median age at first LP was 32 years
(range 4–60). The exact time between onset of the most
recent attack and LP was given for 54 LP and was ≤
30 days in 42 cases; the median interval was 15 days
(range 1–190 days). In 58 additional cases, the exact
time interval was not specified but LP was performed
during an acute attack and thus probably within 30 days
of attack onset. At last follow-up (median observation
period 0 year; range 0–14), more than one attack had
occurred in 27/102 (26.5%) patients. Fifty-eight LP were
performed prior to treatment with steroids or immuno-
suppressants, 4 LP in patients who had been treated
with steroids shortly beforehand, 1 LP in a patient
treated with immunosuppressants and 1 LP in a patient
who had been treated with PEX and steroids 6 months
previously [16]; in the remainder, no treatment was
mentioned.
CSF findings
The most striking finding was a lack of CSF-restricted
OCB in the majority of cases: 65% (52/80) of all patients
were negative for OCB (N=51) or only transiently posi-
tive (N=1) (Table 1). Overall, OCB were absent in 66%
(56/85) of samples. These findings are in stark contrast
to MS, in which CSF-restricted OCB are present in ≥
95% of patients, are thought to remain stable over the
entire course of disease and are considered a diagnostic
mainstay (p < 0.000001 when compared to a reference
work on OCB in MS [17]). Of note, OCB disappeared
later in the disease course in 1/2 initially OCB-positive
patients with available follow-up data. 3/3 initially OCB-
negative patients with follow-up data remained negative
for OCB upon retesting.
Immunosuppressive treatment may theoretically affect
OCB frequency. However, the difference between BCS
patients and MS in terms of OCB positivity was still
highly significant after exclusion of all patients treated
with immunosuppressants (IS) at the time of LP (post
hoc subgroup analysis; corrected p < 0.00001). Moreover,
so far, an effect of IS on OCB positivity in MS has been
shown only for natalizumab [18, 19], which was not used
in any of the patients analysed in this study.
The difference was equally marked when only patients
with both radiological and histopathological evidence for
BCS and thus particularly high diagnostic certainty were
considered (OCB negative in 73.7% [14/19]).
Due to the retrospective nature of the study, MRI
quality varied considerably among cases. To exclude the
possibility that the low rate of OCB was due to uninten-
tional inclusion of patients with diagnoses other than
Table 1 Intrathecal synthesis, cellular immune response and total protein concentrations in BCS and MS
BCS MS p value
Number of patients 132 267 [17] n.a.
Number of samples 146 267 [17] n.a.
Sex ratio (male to female) 1:1.54 1:1.95 [17] n.s.
Median age at first lumbar puncture (range) 32 years (4–60) 36 years [17] n.d.
Relapsing disease course 27/102 (26.5%) n.d. [17] n.d.
CSF-restricted OCB, positive, samples 34.1% (29/85) 98.1% (262/267) [17] < 0.000001
CSF-restricted OCB, positive, patients 35% (28/80) 98.1% (262/267) [17] < 0.000001
CSF-restricted OCB, transiently positive, patients 50% (1/2) n.d. n.a.
Link’s IgG index, elevated, samples 22.6% (7/31) 86.4% (51/59) [20] < 0.000001
Link’s IgG index, elevated, patients 25% (7/28) 86.4% (51/59) [20] < 0.000001
CSF WCC, elevated, samples 28.1% (27/96) 58.4% (156/267) [17] < 0.000001
CSF WCC, median and range, if increased, samples 27/μl (6–371) < 40/μl in 98% [17] n.a.
CSF TP, elevated, samples 40.8% (31/76) n.d. n.a.
CSF TP, median and range, if increased, samples 75 (46–280) n.d. n.a.
ACD, samples 23.6% (17/72) 1.9% (1/54) < 0.0005
ACD albuminocytologic dissociation, BCS Baló’s concentric sclerosis, CSF cerebrospinal fluid, MS multiple sclerosis, n.a. not applicable, n.d. no data, n.s. non-
significant, OCB oligoclonal bands, TP total protein, WCC white cell count
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BCS, we defined (in a fashion blinded to OCB results) a
subgroup of cases with available high-quality MRI
depicting textbook-like BCS lesions (N = 25); all of these
lesions showed three or more layers of demyelination. In
this subgroup of cases with particularly high radiological
confidence, the lack of OCB was even more pronounced
than in the total cohort (OCB negative in 81.8% [18/22];
OCB not tested in 3).
Finally, to rule out any chance that the low OCB rate
found in our study partially reflects differences in sensi-
tivity between current and ‘historic’ methods used to
detect CSF-restricted OCB, we compared the frequency
of OCB in reports published during the past 10 years
with that in the older reports. However, no significant
difference in OCB rates was observed between the
‘current’ and the ‘historic’ subgroup, with an even lower
rate in the ‘current’ subgroup (31 vs. 37%).
We were then interested in whether OCB may define
distinct subgroups of BCS patients. However, no signifi-
cant differences were found between OCB-positive and
OCB-negative patients with regard to sex (male to
female ratio 1:1.8 vs. 1:1.4), median age at onset (32 vs.
30 years), median age at LP (32 vs. 32 years), disease
course at last follow-up (relapsing in 36 vs. 34%), num-
ber of Baló-like lesions (more than one in 48.1 vs.
55.6%), location of Baló-like lesions (presence of infra-
tentorial and/or spinal cord lesions 3.4 vs. 13.7%) and
co-existing non-Baló-like lesion (present in 48.1 vs.
55.6%). While more patients in the OCB-negative group
had an unfavourable outcome (fatal or no/almost no re-
covery in 23.3 vs. 9.5% among OCB-positive patients; N
= 64), the differences did not reach statistical signifi-
cance. Moreover, as a potentially important bias, most
fatal cases were reported in Chinese, Philippine and Jap-
anese patients in the 1980s and early 1990s, when OCB
were not yet generally determined in those countries.
However, if only cases published during the past 20 years
(1998 to 2017) were considered, again, more OCB-
negative than OCB-positive patients had an unfavour-
able outcome (fatal or no/almost no recovery in 20.5 vs.
7.1%; N = 53; p=n.s.).
Conversely, no statistically significant differences in OCB
frequency were found between male and female patients
(31.3 vs. 37.5%), between children/juveniles and adults (50
vs. 32.9%), between patients with a relapsing and patients
with a non-relapsing disease course at last follow-up (36 vs
34%), between LP in patients with a single Baló-like lesion
and in those with multiple Baló-like lesions (36.8 vs 32.4%)
or between LP in patients with additional, non-Baló-like le-
sions and in those without such lesions (36.4 vs 27.6%). A
non-significant trend towards a lower frequency of OCB in
patients with no/almost no recovery or fatal outcome com-
pared with patients who had partial to full recovery at last
follow-up was noted (20 vs. 37.3%; p=n.s.).
In accordance with the widespread lack of IgG OCB,
Link’s IgG index was positive only in 22.6% (7/31) of all
samples tested for that parameter. This is in contrast to
the reference study in MS, which reported an elevated
IgG index in 86.4% (51/59; p < 0.000001) [20].
The CSF WCC was elevated in 27/96 (28.1%) samples.
This compares to a CSF pleocytosis rate in MS of 58.4%
reported in a reference work on CSF in MS (N = 267;
p < 0.000001) [17]. Among patients with pleocytosis and
available data, the median WCC was 27/μl (quartile
range 14.75–32.75). The frequency of OCB was higher
in samples with pleocytosis than in samples without
pleocytosis (58.8 vs. 20%); conversely, the frequency of
CSF pleocytosis was lower in OCB-negative patients
than in OCB-positive patients (55.6 vs. 17.9%; p = 0.013).
TP was elevated in 40.8% (31/76; median 75 mg/dl;
quartile range 54–98.8) of all CSF samples. Most pa-
tients with elevated TP and available data were OCB-
negative (77.8% or 14/18). A so-called ACD, i.e. an in-
crease in the CSF total protein concentration without an
accompanying increase in the number of CSF white
cells, was found in 17/72 (23.6%) samples. ACD is typic-
ally found in Guillain-Barre syndrome but not usually in
MS (ACD in 1/53 [1.9%] LPs in 43 patients with MS
according to McDonald et al., 2001 [45 × RRMS, 8 ×
SPMS]; unpublished data, S.J.; p < 0.0005 vs. BCS). The
majority of patients with ACD and available data (90.9%
or 10/11) were OCB negative. CSF MBP concentration
was determined in seven samples and was elevated in
three (42.9%).
Data on OCB pattern, IgG/A/M CSF and serum con-
centrations and/or QIgG, albumin CSF and serum con-
centrations, lactate CSF concentrations and CSF/serum
antibody indices for measles, rubella or varicella zoster
virus (MRZ reaction) were reported only in single pa-
tients or not at all, preventing systematic analysis of
these CSF parameters.
43.2% (35/81) of all CSF examinations showed neither
pleocytosis nor elevated TP, and 15.1% (11/73) showed
neither CSF pleocytosis or TP elevation nor intrathecal
IgG synthesis. Of note, 12 further LP were classified as
‘normal’ by the authors, but no more detailed informa-
tion was provided. While these LP could not be included
in the statistical analysis, they suggest that the low rate
of WCC pleocytosis, OCB positivity and IgG index ele-
vation observed in our study may even underestimate
the real lack in CSF abnormalities in BCS and, in conse-
quence, the real degree of difference between BCS and
MS in terms of CSF pathology.
Discussion
Traditionally, BCS is considered a variant of MS. Here,
we demonstrate highly significant differences in CSF
profiles between patients with BCS and patients with
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MS. In particular, we found that CSF-restricted OCB, a
qualitative marker of intrathecal IgG synthesis, are missing
in almost two-thirds of patients with BCS (p < 0.000001
compared with MS) and that Link’s IgG index, a quantita-
tive marker of intrathecal IgG synthesis, is negative in
more than 75% of cases (p < 0.000001 compared with
MS). Given that intrathecal IgG synthesis is considered a
diagnostic mainstay of MS [15, 17, 21], our findings chal-
lenge the classification of BCS as a morphological variant
of MS. They rather suggest that BCS is probably caused
by a disorder (or disorders) immunopathogenetically dis-
tinct from MS, at least in the majority of cases.
A very low prevalence of CSF-restricted OCB has also
been found in other diseases that were previously con-
sidered ‘variants’ of MS and are now recognised as
immunologically distinct disease entities in their own
rights by most experts, namely in AQP4-IgG-positive
NMO [3, 4] and in MOG-EM [11] (Fig. 1). The latter
two disorders often meet the clinico-radiological criteria
for MS but differ from conventional MS in terms of
immunopathogenesis and optimum treatment [11, 12,
22–29].
In addition, we found a significantly lower frequency
of CSF pleocytosis in BCS than in MS reference cohorts
(p < 0.000001), further corroborating the notion that
BCS and MS are, in most cases, distinct disorders.
Other CSF parameters, such as CSF and serum levels
of IgG and albumin, QIgG, QAlb (a marker of blood–
CSF barrier function and CSF flow rate) and CSF lactose
levels, were reported in only a few patients, preventing
statistical assessment.
In the effort to better understand the significance of
OCB in BCS, we looked into possible differences be-
tween OCB-positive and OCB-negative patients with
BCS with regard to demographics, disease course, MRI
findings and disease outcome. However, no marked dif-
ferences between the two groups were found in terms of
age at onset, age at the time of LP, sex ratio, disease
course, lesion location or the number of Baló-like lesions
on MRI. Conversely, the rate of OCB-positive samples
did not differ significantly between male and female
patients, relapsing and non-relapsing patients, children
and adults, or patients with a single Baló-like lesion and
patients with multiple Baló-like lesions. However, a non-
significant trend towards an association of OCB negativ-
ity with more severe disease outcome was found.
Why do some patients with BCS exhibit OCB while others
do not?
We first hypothesised that the presence or absence of
intrathecal IgG synthesis might depend on disease activ-
ity, as has been demonstrated in AQP4-IgG-positive
NMOSD [3]. Interestingly, OCB indeed disappeared over
time in one of the only two OCB-positive BCS patients
with available follow-up data on OCB. However, OCB
positivity rates in samples taken within 1 month after
disease onset and samples taken later in the course of
disease did not differ significantly in this study, arguing
prima facie against a major role of disease activity.
Alternatively, BCS lesions may not denote a single dis-
ease entity but may be a (optional or non-optional) final
pathway of various demyelinating diseases, e.g. reflecting
the presence of intralesional hypoxia as recently pro-
posed. If so, BCS lesions could occur in the context of
both conventional (OCB-positive) MS and other (mostly
or exclusively OCB-negative) inflammatory demyelinat-
ing conditions such as MOG encephalomyelitis, ADEM,
NMOSD or other as yet unidentified disorders. In po-
tential keeping with that hypothesis, there was substan-
tial heterogeneity among BCS cases in terms of disease
course (relapsing vs. monophasic), MRI presentation
(additional non-BCS lesions vs. no additional lesions)
and outcome (full recovery vs. fatal). Moreover, some pa-
tients with BCS had initially been diagnosed with MS,
ADEM or NMOSD. Finally, at least some patients with
BCS may suffer from what has been called ‘pattern III’
MS. ‘Pattern III’ MS is diagnosed on the basis of histo-
pathological features, some of which suggest ischemia-
Fig. 1 Frequency of CSF-restricted OCB in MS (N = 276) [17], BCS (present study; N = 146), NMOSD (N = 144) [4] and MOG-EM (N = 45) [11]. AQP4+
aquaporin-4-IgG-positive, AQP4− aquaporin-4-IgG-negative, BCS Baló’s concentric sclerosis, HQ-MRI high-quality MRI subgroup (see the ‘Results’
section for details), MOG-EM myelin oligodendrocyte glycoprotein antibody-positive encephalomyelitis, MS multiple sclerosis, NMOSD neuromyelitis
optica spectrum disorders
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mediated tissue damage, and has only recently been pro-
posed to denote a disease entity distinct from classical
MS based on our observation that patients with ‘pattern
III’ lesions are typically negative for OCB [9]. While
probably overrepresented in biopsy/autopsy samples,
‘pattern III MS’ must be a rare disease in the general MS
population given that OCB are highly frequent in MS. So
far, lesions showing the typical histopathological charac-
teristics of ‘pattern III’ lesions have been reported in 12
patients with ‘concentric demyelination’ [30].
Interestingly, a recent study reported a loss of aquapo-
rin-4 (AQP4) and other astrocytic proteins in BCS,
which in some lesions preceded the loss of myelin, sug-
gesting that BCS might, at least in a subset of cases, be
primarily an astrocytopathy, just as AQP4-IgG-positive
NMO [31]. However, IgG or complement deposits, as
seen in NMO, are usually absent in BCS lesions, and
only a single NMO-IgG-positive patients with BCS le-
sions has been described so far [32].
Our study has both strengths and limitations. Among
its strengths, we count the very high number of LP
examined (given the very low prevalence of the disease)
and the fact that our results were both highly significant
and robust when retested in subgroups with particularly
high diagnostic certainty (see the ‘Results’ section for de-
tails). With no differences between historic and more
current patients in terms of OCB frequency and only
very few patients having been treated at the time of LP,
we can also broadly rule out an effect of assay sensitivity
or treatment; moreover, the very high rate of OCB in
classic MS is not a new finding linked to modern tech-
niques but was reported in studies performed as early as
some of the earliest BCS studies analysed here.
On the other hand, one may count the retrospective
nature of our study and the fact that the patients in-
cluded in the analysis were seen at many different cen-
tres among the potential limitations. However, it is
virtually impossible to perform a large prospective
single-centre study on BCS given the condition’s very
low prevalence. Moreover, the study’s retrospective ‘mul-
ticentre’ setting reduced potential risks resulting from
centre-specific selection bias, a problem inherent to
single-centre studies. Second, no CSF results were given
in numerous reports on BCS in the previous literature.
This might have introduced a bias towards cases with
pathological CSF findings. However, this would imply that
our results actually underestimate the observed lack of
OCB, IgG index elevation and WCC pleocytosis in BCS
and would thus make our findings even more relevant.
The present study focused on immunological parame-
ters routinely tested in patients with MS and BCS. Fur-
ther immunological studies aiming at investigating the
differences between BCS and MS in terms of immuno-
pathogenesis in greater detail are now required.
It is reassuring that our results are in agreement with
a previous much smaller study performed on behalf of
the MAGNIMS network [33]. Following another ap-
proach and focusing on MRI findings, the authors iden-
tified 69 adult patients with ‘atypical idiopathic
inflammatory demyelinating lesions’ and high-quality
MRI data in the English-language literature published
between 1984 and 2004 and retrospectively classified 11
of them as having BCS based on typical MRI. Of those
11 BCS patients, only 9%, i.e. one patient, had OCB.
Conclusion
In summary, our study demonstrates significant differ-
ences in CSF findings between patients with BCS and
patients with MS, especially in terms of intrathecal IgG
synthesis. This suggests differences in immunopathogen-
esis between BCS and MS and supports the notion of
Baló-like lesions denoting the presence of a disorder im-
munologically distinct from MS in most cases. This
could have clinically important diagnostic, nosological,
prognostic and therapeutic implications. Of note, the
OCB frequency in BCS is more similar to that reported
in NMOSD and MOG-EM than in classic MS (Fig. 1).
Further studies are now warranted to confirm these
findings in a prospective manner as well as to look into
potential differences between OCB-negative and OCB-
positive patients with BCS in more detail. Given the rar-
ity of the condition, this will require an international
multicentre approach. Our results provide the rationale
for such studies.
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